Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$3.45M, compared with -$9.93M a year earlier. Trailing-twelve-month income before tax was -$27.37M.

Context

  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$3.45M or moves back toward the trailing-twelve-month quarterly average of -$6.84M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.45M+46.6% QoQ
Last fiscal yearDec 2025
-$33.85M+39.4% YoY
LTMMar 2026
-$27.37M+52.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.2%——
1 year+39.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(33.85M) USD
Year-over-year change
+39.4%

Income Before Tax vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.6% is the 2nd highest of 10, against a peer median of -15.2%.
ALDX Competitors
Income Before Tax for ALDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
GNLXGenelux CorporationLTM Mar 2026-$31.78M USD-7.7%—397225.0%
AMRNAmarin Corporation plcLTM Mar 2026-$34.72M USD+57.8%—16.2%
MREOMereo BioPharma Group plcLTM Mar 2026-$35.79M USD+25.0%—7158.7%
CADLCandel Therapeutics, Inc.LTM Mar 2026-$54.42M USD-37.5%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.44M USD-17.3%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.2%—1788.8%
CLLSCellectis S.A.LTM Mar 2026-$69.45M USD-15.2%—102.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$74.31M USD-17.6%——
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$156.4M USD-7.6%——
Peer median (excluding ALDX) —-15.2%—4473.8%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development44.94M47.31M29.46M48.22M25.66M
Selling, General & Admin11.28M15.37M13.34M11.89M9.6M
Operating Expenses56.22M62.68M42.79M60.12M35.27M
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
EBITDA(55.77M)(60.07M)(35.21M)(53.68M)(31.69M)
EBITDA Margin—————
Operating Income(56.22M)(62.68M)(42.79M)(60.12M)(35.27M)
Operating Margin—————
Interest Income185.36K2.35M7.32M6.19M3.32M
Interest Expense1.74M1.69M2.07M1.93M1.91M
Other Income / Expenses(1.56M)655.35K5.25M4.27M1.42M
Income Before Tax(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Net Margin—————
EPS (Basic)(1.07)(1.06)(0.64)(0.94)(0.56)
EPS (Diluted)(1.07)(1.06)(0.64)(0.94)(0.56)
Weighted Avg Shares54.04M58.41M58.94M59.48M60.06M
Weighted Avg Shares (Diluted)54.04M58.41M58.94M59.48M60.06M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.